Introduction
Gram-negative bacteraemia is associated with a mortality rate in excess of 20%. 1, 2 This is of concern because the number of Gram-negative bacteraemias is rising 3 and the prevalence of resistance is increasing. 4 Several studies have found that inadequate therapy is associated with an adverse outcome, 1, 2, 5, 6 though other studies have not found such a relationship. [7] [8] [9] In an attempt to control Clostridium difficile infection (CDI), we introduced an antibiotic stewardship programme in April 2008. This involved regular hospital-wide antibiotic review rounds conducted by a Consultant Microbiologist and Antibiotic Pharmacist, restricting the use of second-and third-generation cephalosporins and launching a new antibiotic guideline. This, in addition to other measures (increased education, hand hygiene audits, use of personal protective equipment, enhanced cleaning with hypochlorite), resulted in a 62% reduction in cases of CDI over the period 2007-08 to 2008-09. In this study, we sought to determine the effectiveness and level of compliance with the new guidelines and its impact on survival among patients with Gram-negative bacteraemia.
Patients and methods

Setting
Peterborough and Stamford Hospitals NHS Foundation Trust is a district general hospital with 600 beds including acute medical, surgical (general and orthopaedic), elderly care, women's services and intensive care. It covers a predominantly semi-rural population of 450 000 people in Cambridgeshire, England, with $75 000 admissions per year.
Study design and patients
An uncontrolled prospective observational study of all Gram-negative bacteraemias occurring in adults >18 years of age for the year commencing 1 July 2008 was performed. The decision to take blood cultures was at the discretion of the clinician attending the patient. All Gram-negative bacteraemias were reviewed by a Consultant Microbiologist on receipt of the initial result and antibiotics changed to reflect the guidelines if non-compliant. The empirical treatment was likely to be modified at this point, or the following day, when the susceptibility results were available. Therefore, patients rarely received inadequate therapy for >48 h. Approval for the study was obtained from the Trust's audit committee.
Variables
Demographic data, clinical details and the antibiotic history were obtained from laboratory and microbiology records and medical, nursing and pharmacy notes as well as the patient administration system. 
Definitions
Bacteraemias were counted as one episode if they occurred within 14 days of a previous result (with the same organism and antibiogram). Subsequent episodes occurring after this time were considered new episodes and considered to be recurrences (with the same organism and antibiogram). Blood cultures growing more than one organism were defined as mixed. Community-onset bacteraemia was defined as that occurring within 48 h of admission if the patient was not transferred from another hospital, whereas hospital-onset bacteraemia was after this period. Healthcare-associated bacteraemia was defined as blood cultures taken within 48 h of hospital admission from a patient who had previously been admitted to hospital in the preceding year or from a nursing home. Shock was defined as sepsis associated with evidence of organ hypoperfusion and a systolic blood pressure of <90 or >30 mmHg less than the baseline that did not respond to fluid treatment and required vasoactive drug therapy.
Empirical therapy was considered adequate if the agent(s) initially given had in vitro activity against the organism subsequently identified. Length of stay was defined as days after blood culture taken until discharge.
Microbiology
Microbiology data were obtained from the laboratory information system. All blood cultures were processed using the BacT/Alert 3D system (bioMérieux UK Ltd, Basingstoke, UK). Organisms were identified to species level by API20E or API20NE (bioMérieux UK Ltd,). Routine antibiotic susceptibility testing was performed according to British Society for Antimicrobial Chemotherapy (BSAC) methodology. Antibiotics tested included amoxicillin, co-amoxiclav, ciprofloxacin, trimethoprim, gentamicin, cefuroxime, ceftazidime, ceftriaxone, piperacillin-tazobactam and meropenem. Isolates that were resistant to one or more cephalosporin were tested for the presence of extended spectrum b-lactamase (ESBL) by double-disc diffusion.
The hospital antibiotic guidelines (limited to relevant indications only) recommend the combination of gentamicin and co-amoxiclav (or gentamicin and ciprofloxacin if penicillin allergic) for empiric treatment of severe urinary tract infection or pyelonephritis, biliary and abdominal sepsis and sepsis of unknown source. Amoxicillin is recommended for early onset hospital-acquired pneumonia (onset within 4 days of admission, co-amoxiclav for late onset and piperacillin-tazobactam for ventilatorassociated pneumonia). Piperacillin-tazobactam (or ciprofloxacin) AE gentamicin is the empirical treatment of choice for neutropenic sepsis. Co-amoxiclav is recommended for the treatment of moderate diabetic foot infections with piperacillintazobactam reserved for severe diabetic foot infections. Vancomycin and gentamicin is recommended for suspected line infection, while meropenem is recommended in patients with prior ESBL colonization.
Statistical analysis
Chi-square test was used to compare qualitative baseline variables (demographics, risk factors, comorbidities and adequacy of guidelines) between adequate and inadequate therapies whereas the two sample t-test was used for quantitative variables (Charlson comorbidity score and albumin). We compared rate of death at discharge between adequate and inadequate therapies by using KaplanMeier product-limit estimator, which calculated the cumulative probability of death at discharge for each group and we used both the Wilcoxon Log-rank statistics to determine whether the difference in death at discharge between the groups was significant. Since both yielded similar results, we report the Wilcoxon in this analysis. Unconditional logistic regression was used to model the outcome variables (recurrence, death within 1 week and death within 30 days) after adjusting for significant baseline variables (P < 0.1 after univariate analysis). Additionally, adjusted hazards ratio was derived to compute difference in risk of death at discharge between the two groups. We employed Proc Logistic for the unconditional logistic regression modelling, and Proc PHREG to generate the hazards ratios using SAS software (SAS Institute, Inc., Cary, NC, USA, version 9.2). We constructed the logistic regression models and assessed goodness-of-fit of the regression models using the -2 log likelihood ratio test, and estimated the significance of main effects by means of the Wald test. 10 For the hazards models, we tested for the non-violation of the proportionality assumption in each case. We confirmed this by plotting the log-negative-log of the Kaplan-Meier estimates of the survival function versus the log of time. The resulting curves were parallel. Furthermore, we used analysis of covariance to compare the mean duration of hospital stay post-bacteraemia among survivors after adjusting for baseline variables that were considered important in the study. Regardless of the regression model type, we assessed the possibility of model over fitting using stepwise procedures. All tests of hypothesis were two-tailed with a type-1 error rate fixed at 5%.
Results
Patient population
There were 227 bacteraemias (203 episodes) in 190 patients in the study period. Of these, 13 had a recurrence; 15 were mixed infections [with enterococci (5), coagulase negative staphylococci (5), Streptococcus spp. (4) and Staphylococcus aureus (1)]. The mean age was 71.1 years (median 74 years; range 18-99). Of the total patients, 89 (46.8%) were female. Forty-seven episodes were community acquired, 101 were healthcare associated and 55 were hospital-acquired. A total of 130 patients (138 episodes) were medical, 29 (30 episodes) were surgical, 20 (24 episodes) were cancer, 8 were (ICU), 2 were gynaecological and 1 was orthopaedic. The source was urinary tract (95 episodes; 46.8%), biliary tract (25; 12.3%), pneumonia (20; 9.8%), bowel (18; 8.9%), wound (9; 4.4%), line (8; 3.9%), bone and joint (2; 1%), liver abscess (1; 0.5%) and unknown in 25 (12.3%) cases. Table 1 shows the location of the patient when the blood culture was taken and the source of bacteraemia.
Clinical features and comorbidities
Fifty-four patients had a non-fatal underlying disease, 97 had an ultimately fatal underlying disease, 20 had a rapidly fatal underlying disease and 32 had no underlying disease. Renal disease was the underlying condition in 56 (27.6%) episodes, malignant solid tumour in 56 (27.6%) episodes, cardiac disease in 52 (25.6%) episodes and diabetes in 47 (23.2%) episodes. Anaemia was present in 89 (43.8%) episodes, a urinary catheter in 78 (38.4%), 75 (36.9%) were in a dependent functional state and 63 (31%) were attended by a district nurse. Fifty nine were immunosuppressed (29.1%). Four episodes (in four patients) (2%) had no risk factors or past medical history.
The mean Charlson comorbidity score was 4 (median 3; range 0-12). The white cell count was low (<4 Â 10 9 /l) in 23/194 (11.9%) episodes and raised (>11 Â 10 9 /l) in 115 (59.3%) episodes. Albumin was low (<31 g/l) in 64/154 (41.6%) episodes (mean 32 g/l; range 12-48 g/l) and the C-reactive protein (CRP) was raised in 180/194 (92.8%) episodes (>10 mg/l; mean 182 mg/l, range <10-538 mg/l). The peak temperature was !388C in 133 (65.5%) episodes.
Microbiology
Escherichia coli was the most frequent pathogen identified (122 episodes; 60%) followed by Klebsiella spp. (24; 11.8%), Pseudomonas aeruginosa (14; 6.9%), Proteus spp. (14; 6.9%), Citrobacter spp. (7; 3.4%), Acinetobacter spp. (6; 3%), Enterobacter spp. (6; 3%), Serratia spp. (4; 2%), Morganella morgannii (3; 1.5%), Pseudomonas putida (2; 1%) and Salmonella paratyphi A (1; 0.5%).
Resistance to amoxicillin occurred in 139/203 episodes (68.5%), co-amoxiclav (67; 33%), trimethoprim (80; 39.4%), ciprofloxacin (26; 12.8%), cefuroxime (44; 21.7%), gentamicin (7; 3.5%), piperacillin-tazobactam (9; 4.4%); no resistance to meropenem was observed. Co-amoxiclav and gentamicin (combined) resistance occurred in three episodes (1.4%) and ciprofloxacin and gentamicin (combined) resistance occurred in 6 (2.9%) episodes. There were seven isolates that produced ESBL (in six episodes) in the study period.
Empirical antibiotic treatments
The most frequent empirical antibiotic treatments were co-amoxiclav and gentamicin 
Adequacy of guidelines
The guidelines were adequate and sufficient to guide empiric therapy for 194/203 (95.6%) episodes. The guidelines were not helpful for conditions where Gram-negative sepsis was not suspected (five patients had community-acquired pneumonia and two patients had cellulitis). Guidelines were not applicable for the two patients with bone and joint infection.
Adequacy of therapy
Overall, 163 episodes (80.2%) received adequate therapy. Of the 40 episodes where empiric therapy was inadequate, 5 episodes were treated with trimethoprim alone and 2 did not receive initial antibiotic therapy. Thirty-three received antibiotics without activity against the isolate-18 received no gentamicin, 2 patients had gentamicin and co-amoxiclav resistant strains, 1 patient with hospital-acquired pneumonia had a co-amoxiclav-resistant strain, 3 diabetic patients with ulcers received flucloxacillin instead of co-amoxiclav or piperacillin-tazobactam, 8 received penicillin or amoxicillin for community-acquired pneumonia and 1 patient with intra-abdominal sepsis received clindamycin and metronidazole. Table 2 shows differences between these groups of individuals. Of the 18 patients who received co-amoxiclav with no gentamicin, 8 patients had cefuroxime susceptible strains and 2 of these died.
Compliance with guidelines
Guidelines were followed in 115/203 (57%) episodes. Gentamicin was not used in 55 (21.7%) 
Differences between the adequately and inadequately treated groups
The prevalence of anaemia and immunosuppression was higher in the adequate therapy group whereas the inadequate therapy group had higher rates of diabetes ( Table 2 ). The prevalence of the remaining baseline variables was not different in the two groups. Additionally, the means for Charlson comorbidity score, albumin, CRP, age in years and length of stay were not significantly different between the two groups (Table 3 ).
Outcome
Twenty-four patients (12%) died within 7 days and 45 (22%) died within 30 days. Figure 1 presents adjusted odds ratios (ORs) between adequate and inadequate therapies. Patients in the inadequate therapy group had >2-fold elevated risk of death [OR = 2.63, 95% confidence interval (CI) =1.09-6.34] within 30 days and >6-fold increase risk of death (OR = 6.40, 95% CI = 2.22-18.45) within 1 week when compared to patients in the adequate therapy group. This result was also consistent with the Kaplan-Meier product-limit estimator curves that had a P-value of 0.07 for difference in survival at time of discharge for adequate and inadequate therapies (Figure 2) .
Eighteen patients required ICU admission due to a variety of factors (not recorded), 25 required surgery and 13 developed a recurrence. Even though the recurrence rate was higher in the inadequate therapy group, the risk did not reach statistical significance, even after controlling for covariates that were deemed important. Patients who received adequate therapy were in hospital for a median of 11 days after the blood culture (range 0-104 days) compared to a median of 8 days for those receiving inadequate therapy (range 0-49 days). Twenty-five patients required a surgical procedure. Ten patients required an endoscopic retrograde cholangiopancreatography, 7 required nephrostomies with stent insertion, 3 required drainage of abscesses, 3 required debridement, 1 required line removal and 1 required a colectomy.
Discussion
In our institution, Gram-negative bacteraemia is associated with significant mortality of 11.8% within 1 week and 21.7% within 4 weeks. We found a statistically significant difference in mortality at 1 and 4 weeks between patients receiving adequate and inadequate antimicrobial therapy. We found no difference in terms of recurrence and requirement for surgery or ICU.
This study highlights the impact of a new antibiotic stewardship programme instituted to reduce C. difficile cases in terms of improved outcome. It also demonstrates the importance of adopting guidelines based on local susceptibility patterns. Adherence to the guidelines was associated with the correct empirical antibiotic choice and a significantly lower mortality.
This study further confirms the importance of adequate antimicrobial therapy in the first 24 h and the importance of using a second agent (gentamicin) in our specific population. Of note is that all patients were reviewed by a consultant microbiologist between 24 and 48 h of a positive blood culture and treatment modified. Therefore, this suggests that adequate therapy during the first 24 h is crucial to survival. This is described in patients with septic shock. A retrospective study (over 15 years) of 2154 patients with septic shock found that mortality was 20.1% in those who received antibiotics in the first hour and rose by 7.6% per additional hour's delay. 11 Lodise and colleagues suggest mortality was increased after a delay of 52 h in a retrospective study of 100 patients with P. aeruginosa bacteraemia. This was identified by classification and regression tree analysis. 12 The guidelines were adequate or applicable in 194/203 (95.6%) episodes, but were followed in only 57% of episodes. The principal reason for this was failure to administer gentamicin. Co-amoxiclav monotherapy, with its resistance rate in excess of 30% is inadequate in this population. Amoxicillin was recommended for early-onset hospital-acquired pneumonia. This audit revealed resistance rates approaching 70%. We used amoxicillin for this indication as it covers 98% of pneumococci and 80% of Haemophilus influenzae in our population, common community pathogens of early hospitalacquired pneumonia. In the light of the findings of this audit, however, we have reviewed our empiric antibiotic guideline so that amoxicillin is reserved for mild to moderate cases, while co-amoxiclav is employed for severe cases of hospital-acquired pneumonia.
While 21.7% of episodes were cefuroxime resistant, cefuroxime would potentially have reduced the Figure 2 . Kaplan-Meier product-limit estimator curves for survival probabilities of death at discharge among patients receiving adequate and inadequate therapy. 9 ). The principal reason for failing to use gentamicin was concerns over toxicity in patients with impaired renal function. This is a perceived risk as there was no difference in renal function between the two groups. Diabetes was a risk factor for inadequate therapy; diabetes may have influenced the decision on using gentamicin, which could perhaps be explained by its association with renal impairment; renal disease was found in 14/49 (28.6%) of diabetics.
Immunosuppression was associated with adequate therapy. This could be partly explained by the large number of single specialty (oncology) patients. This may reflect better adherence to guidelines by oncologists as 21 of 24 episodes in cancer patients followed policy and received adequate therapy. Anaemia was also associated with adequate therapy reflecting the high incidence of anaemia among this patient group. Anaemia was present in 16 (66.7%) of 24 bacteraemia episodes among cancer patients and in 36/59 (61%) of immunosuppressed patient episodes.
Several retrospective studies have found a difference in mortality between patients receiving inadequate therapy versus those receiving adequate therapy.
1,2,6,12-15 Four studies have found no difference in in-hospital mortality and length of stay between adequately and inadequately treated cohorts. [7] [8] [9] 16 This study was controlled for many variables and we provided several endpoints for outcome. This is in contrast to other studies where a variety of endpoints were used, making comparisons difficult. Its prospective nature means the data are robust and complete. It is comparable in size to other studies and we did not limit our study to one or two particular species or resistant strains. Only one study has been previously performed in a district hospital setting. 6 No new intervention measures were instituted during the study period (unlike several of the other studies due to their long study period).
This is a single centre study with low rates of multi-drug resistance, so its results may not be applicable to other institutions. Its observational nature may have missed important confounding biases, such as renal stones, a known risk factor for urinary tract infection. Whilst a randomized trial would reduce this risk we could not justify this for ethical reasons. We did not try to determine attributable mortality as this was not an objective and we did not perform long-term follow-up. A further limitation is the impact of multiple comparisons on our estimates since about seven outcomes were assessed in this study. However, it is noteworthy that à priori analysis restricted to the primary outcomes (mortality) yielded summary estimates similar to subsequent analyses that added morbidity events (secondary outcomes) as well. It is therefore, unlikely that the results for our primary outcomes (mortality), which were found to be significant, were influenced by subsequent multiple comparisons that encompassed morbidity events. This is the first study to demonstrate the safety and effectiveness of new UK-wide antimicrobial strategies targeted at reducing C. difficile rates. Inadequate therapy is associated with increased mortality at 1 week and 30 days. Our findings also provide further support for the key elements of the on going 'Surviving Sepsis Campaign', namely early and appropriate antimicrobial therapy. Further work is required in our trust to improve compliance with the guidelines. Further studies are also required to determine the optimum therapy for patients at risk of C. difficile.
